<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cspc Pharmaceutical Group Limited — News on 6ix</title>
    <link>https://6ix.com/company/cspc-pharmaceutical-group-limited</link>
    <description>Latest news and press releases for Cspc Pharmaceutical Group Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 30 Jul 2025 09:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cspc-pharmaceutical-group-limited" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d96d10d20c3ebdd60f9b28.webp</url>
      <title>Cspc Pharmaceutical Group Limited</title>
      <link>https://6ix.com/company/cspc-pharmaceutical-group-limited</link>
    </image>
    <item>
      <title>Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited</title>
      <link>https://6ix.com/company/cspc-pharmaceutical-group-limited/news/madrigal-pharmaceuticals-enters-into-exclusive-global-license-agreement-for-oral-glp-1-receptor-agonist-with-cspc-pharmaceutical-group-limited</link>
      <guid isPermaLink="true">https://6ix.com/company/cspc-pharmaceutical-group-limited/news/madrigal-pharmaceuticals-enters-into-exclusive-global-license-agreement-for-oral-glp-1-receptor-agonist-with-cspc-pharmaceutical-group-limited</guid>
      <pubDate>Wed, 30 Jul 2025 09:00:00 GMT</pubDate>
      <description>License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a once-a-day, well-tolerated pill CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreemen</description>
    </item>
  </channel>
</rss>